半胱氨酸蛋白酶抑制剂SN的功能及其与肿瘤的关系

doi:10.3760/cma.j.issn.1673422X.2017.03.011

国际肿瘤学杂志 ›› 2017, Vol. 44 ›› Issue (3): 201-204.doi: 10.3760/cma.j.issn.1673422X.2017.03.011

半胱氨酸蛋白酶抑制剂SN的功能及其与肿瘤的关系

姜姗姗,辛彦

110001 沈阳，中国医科大学附属第一医院肿瘤研究所胃肠肿瘤病理研究室，普通外科研究所肿瘤病理研究室

出版日期:2017-03-08 发布日期:2017-02-28
通讯作者: 辛彦 E-mail:yxin@mail.cmu.edu.cn
基金资助:
国家自然科学基金（81071650、30973503）；辽宁省科技厅科学技术计划

（2013225303103、20114040133）

Function of Cystatin SN and its relationship with tumors

Jiang Shanshan, Xin Ya

Laboratory of Gastrointestinal OncoPathology of Cancer Institute and General Surgery Institute, First Affiliated Hospital of China Medical University, Shenyang 110001, China

Online:2017-03-08 Published:2017-02-28
Contact: Xin Yan E-mail:yxin@mail.cmu.edu.cn
Supported by:
National Natural Science Foundation of

China (81071650, 30973503); Special Foundation for Science and Technology

Program in Liaoning Province of China (2013225303103, 20114040133)

摘要/Abstract

摘要： 半胱氨酸蛋白酶抑制剂SN（Cystatin SN）是一种由CST1编码的分泌型蛋白，具有促进细胞衰老凋亡的活性，在蛋白水解酶活性调控中发挥重要作用。许多研究发现，Cystatin SN在多种类型肿瘤中存在异常表达，且与肿瘤发生、发展密切相关。 Cystatin SN可能在肿瘤的诊断和预后评估中发挥重要作用。

关键词: 半胱氨酸蛋白酶抑制剂, 肿瘤, 功能

Abstract: Cysteine protease inhibitor SN (Cystatin SN) is a secretory protein encoded by CST1, with the promotion of cell senescence and apoptosis activity, playing an important role in the regulation of proteolytic activity. Many studies have found that Cystatin SN is abnormally expressed in various kinds of tumors, and is closely related with the tumorigenesis and progression. Cystatin SN may play an important role in the diagnosis and prognosis of tumors.

Key words: Cysteine proteinase inhibitors, Neoplasms, Function

姜姗姗,辛彦. 半胱氨酸蛋白酶抑制剂SN的功能及其与肿瘤的关系[J]. 国际肿瘤学杂志, 2017, 44(3): 201-204.

Jiang Shanshan, Xin . Function of Cystatin SN and its relationship with tumors[J]. Journal of International Oncology, 2017, 44(3): 201-204.

参考文献

［1］ Kim JT, Lee SJ, Kang MA, et al. Cystatin SN neutralizes the inhibitory effect of cystatin C on cathepsin B activity［J］. Cell Death Dis, 2013, 4: e974. DOI: 10.1038/cddis.2013.485. ［2］ Nandy SK, Bhuyan R, Seal A. Modelling family 2 cystatins and their interaction with papain［J］. J Biomol Struct Dyn, 2013, 31(6): 649-664. DOI: 10.1080/07391102.2012.706403. ［3］ Magister S, Kos J. Cystatins in immune system［J］. J Cancer, 2013, 4(1): 45-56. DOI: 10.7150/jca.5044. ［4］ SousaPereira SP, Abrantes J, Pinheiro A, et al. Evolution of C, D and Stype cystatins in mammals: an extensive gene duplication in primates ［J］. PLoS One, 2014, 9(10): e109050. DOI: 10.1371/journal.pone.0109050. ［5］ Morzel M, Chabanet C, Schwartz C, et al. Salivary protein profiles are linked to bitter taste acceptance in infants［J］. Eur J Pediatr, 2014, 173(5): 575-582. DOI: 10.1007/s004310132216z. ［6］ de SousaPereira SP, Amado F, Abrantes J, et al. An evolutionary perspective of mammal salivary peptide families: cystatins, histatins, statherin and PRPs［J］. Arch Oral Biol, 2013, 58(5): 451-458. DOI: 10.1016/j.archoralbio.2012.12.011. ［7］ Manconi B, Cabras T, Pisano E, et al. Modifications of the acidic soluble salivary proteome in human children from birth to the age of 48 months investigated by a topdown HPLCESIMS platform［J］. J Proteomics, 2013, 91(91): 536-543. DOI: 10.1016/j.jprot.2013.08.009. ［8］ Dsamou M, Morzel M, Le Corre L, et al. Caffeine increases the expression of cystatin SN in human submandibular acinarlike HSG cells［J ］. Arch Oral Biol, 2013, 58(10): 1511-1516. DOI: 10.1016/j.archoralbio.2013.06.005. ［9］ Sanna M, Firinu D, Manconi PE, et al. The salivary proteome profile in patients affected by SAPHO syndrome characterized by a topdown RPHPLCESIMS platform［J］. Mol Biosyst, 2015, 11(6): 1552-1562. DOI: 10.1039/c4mb00719k. ［10］ Dsamou M, Palicki O, Septier C, et al. Salivary protein profiles and sensitivity to the bitter taste of caffeine［J］. Chem Senses, 2012, 37(1): 87-95. DOI: 10.1093/chemse/bjr070. ［11］ Fornander L, Graff P, Whlén K, et al. Airway symptoms and biological markers in nasal lavage fluid in subjects exposed to metalworking fluids［J］. PLoS One, 2013, 8(12): e83089. DOI: 10.1371/journal.pone.0083089. ［12］ Imoto Y, Tokunaga T, Matsumoto Y, et al. Cystatin SN upregulation in patients with seasonal allergic rhinitis［J］. PLoS One, 2013, 8(8): e67057. DOI: 10.1371/journal.pone.0067057. ［13］ Yoneda K, Iida H, Endo H, et al. Identification of cystatin SN as a novel tumor marker for colorectal cancer［J］. Int J Oncol, 2009, 35(1): 33 -40. ［14］ Jiang J, Liu HL, Liu ZH, et al. Identification of cystatin SN as a novel biomarker for pancreatic cancer［J］. Tumour Biol, 2015, 36(5): 3903 -3910. DOI: 10.1007/s1327701430333. ［15］ Cao X, Li Y, Luo RZ, et al. Expression of cystatin SN significantly correlates with recurrence, metastasis, and survival duration in surgically resected nonsmall cell lung cancer patients［J］. Sci Rep, 2015, 5: 8230. DOI: 10.1038/srep08230. ［16］ Blanco MA, Leroy G, Khan Z, et al. Global secretome analysis identifies novel mediators of bone metastasis［J］. Cell Res, 2012, 22(9): 1339-1355. DOI: 10.1038/cr.2012.89. ［17］ Liu XF, Xiang L, Zhang Y, et al. CAPC negatively regulates NFκB activation and suppresses tumor growth and metastasis［J］. Oncogene, 2012, 31(13): 1673-1682. DOI: 10.1038/onc.2011.355. ［18］ Keppler D, Zhang J, Bihani T, et al. Novel expression of CST1 as candidate senescence marker［J］. J Gerontol A Biol Sci Med Sci, 2011, 66 (7): 723-731. ［19］ Chen YF, Ma G, Cao X, et al. Overexpression of cystatin SN positively affects survival of patients with surgically resected esophageal squamous cell carcinoma［J］. BMC Surg, 2013, 13: 15. DOI: 10.1186/147124821315. ［20］ Choi EH, Kim JT, Kim JH, et al. Upregulation of the cysteine protease inhibitor, cystatin SN, contributes to cell proliferation and cathepsin inhibition in gastric cancer［J］. Clin Chim Acta, 2009, 406 (12): 45-51. DOI: 10.1016/j.cca.2009.05.008. ［21］ Pramanik KC, Fofaria NM, Gupta P, et al. Inhibition of βcatenin signaling suppresses pancreatic tumor growth by disrupting nuclear βcatenin/TCF1 complex: critical role of STAT3［J］. Oncotarget, 2015, 6(13): 11561-11574. DOI: 10.18632/oncotarget.3427. ［22］ Mullapudi N, Ye B, Suzuki M, et al. Genome wide methylome alterations in lung cancer［J］. PLoS One, 2015, 10(12): e0143826. DOI: 10.1371/journal.pone.0143826. ［23］ Kim YI, Lee J, Choi YJ, et al. Proteogenomic study beyond chromosome 9: new insight into expressed variant proteome and transcriptome in human lung adenocarcinoma tissues［J］. J Proteome Res, 2015, 14(12): 5007-5016. DOI: 10.1021/acs.jproteome.5b00544

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

半胱氨酸蛋白酶抑制剂SN的功能及其与肿瘤的关系

Function of Cystatin SN and its relationship with tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价